Sesen Bio, Inc. - Special Call Transcript
Good day, everyone, and welcome to Sesen Bio July 2020 Business Update Call. (Operator Instructions)
I would now like to turn the call over to your host, Erin Clark. Please go ahead, ma'am.
Thank you and good morning, everyone. On today's call, we will discuss key corporate updates, including the Sesen Bio and Qilu Pharmaceutical license agreement. Joining me on today's call are Dr. Thomas Cannell, President and Chief Executive Officer; Dr. Chad Myskiw, Executive Director of CMC; and Monica Forbes, our Chief Financial Officer.
Earlier this morning, we issued a press release outlining some of the highlights that will be covered on the call today. The press release and the slides to which we will refer are available in the Investors section of the company's website at sesenbio.com.
Before we begin, I'd like to remind you that today's discussion will include forward-looking statements related to the company's current plans and expectations, which are subject to risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
